Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most significant unresolved ...

Several controversial advertisements placed on public streets have prompted incessant complaints from Long Beach residents: ...

국산 1호 키메릭항원수용체-T(CAR-T) 치료제인 큐로셀의 '림카토'가 건강보험 급여 적용을 위한 첫 관문을 넘었다. 최종 급여가 확정된 건 아니지만 수억원에 이를 것으로 예상되는 고가의 첨단의약품에 대한 환자 접근성이 ...

AbClon announced on July 6 that its 'core technology related to CD30-targeting chimeric antigen receptor T-cell (CAR-T) ...

The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities. It has nominated a lead candidate in the in vivo ...

Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, ...

Cellular immunotherapy uses a patient's own immune cells, including genetically engineered CAR-T, to recognize and destroy cancer cells, and it has emerged as one of the most transformative advances ...